Cat. No. 4034
Biological ActivityPeptide that reverses the anticoagulant effect of heparin (Cat. No. 2812). Potently binds heparin (Kd = 36 nM in vitro).
Licensing InformationSold under license
(Modifications: Ala-1 = N-terminal Ac, Ala-19 = ε-Ac, X-36 = Dpr, Ala-37 = β-Ac, Glu-53 = C-terminal Amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Cushing et al (2010) Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist. Eur.J.Pharmacol. 635 165. PMID: 20307530.
Schick et al (2004) Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Blood 103 4.
Shenoy et al (1999) Development of heparin antagonists with focused biological activity. Curr.Pharmaceut.Des. 5 965.
If you know of a relevant reference for PM 102 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses PM 102 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: PM 102, supplier, PM102, heparin, antagonists, anticoagulants, HepArrest, Tocris Bioscience, Cell Adhesion Molecule products